Verona

• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• Bioequivalence study on aqueous humour concentrations of active ingredients after topical application of LEVIOSA® versus F2904. Randomized, … Ended
  2023-503722-39-00 2 2024-04-22 Cataract
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM) Ended
  2022-502835-21-00 4 2024-02-23 cystic fibrosis bronchiectasis
• A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te … Ended
  2022-502467-38-00 4 2024-02-22 Non-small cell lung cancer (NSCLC)
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple … Ended
  2023-507454-33-00 1 2024-01-08 Neurodevelopmental disorder
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Stand … Ended
  2022-502615-11-00 1 2023-11-29 Locally Advanced or Metastatic Solid Tumors
• A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moder … Ended
  2022-502880-39-00 4 2023-11-13 Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Parti … Ended
  2022-500568-37-00 5 2023-10-11 Masseter Muscle Prominence
• A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The … Ended
  2024-512767-30-00 4 2023-09-28 Eosinophilic Esophagitis
• A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O … Ended
  2022-502546-26-00 3 2023-09-11 Sickle Cell Disease
• A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors Ended
  2022-502891-22-00 1 2023-08-02 Advanced Solid Tumors
• Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended
  2023-503494-38-00 5 2023-07-20 Tourette’s Disorder
• ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended
  2022-502267-37-00 9 2023-07-17 metastatic colorectal cancer
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended
  2022-501425-20-00 4 2023-04-03 Rheumatoid Arthritis Arthritis Joint Diseases Musculoskeletal Disea
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 Metastatic melanoma
• A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended
  2024-512202-25-00 4 2023-02-27 Irritability associated with autistic disorder in children and adolesc
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 4 2023-01-17 Asthma
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura

Showing 385–408 of 440 trials